Cargando…

Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies

Irreproducibility of preclinical findings could be a significant barrier to the “bench-to-bedside” development of oncolytic viruses (OVs). A contributing factor is the incomplete and non-transparent reporting of study methodology and design. Using the NIH Principles and Guidelines for Reporting Prec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fergusson, Dean A., Wesch, Neil L., Leung, Garvin J., MacNeil, Jenna L., Conic, Isidora, Presseau, Justin, Cobey, Kelly D., Diallo, Jean-Simon, Auer, Rebecca, Kimmelman, Jonathan, Kekre, Natasha, El-Sayes, Nader, Krishnan, Ramya, Keller, Brian A., Ilkow, Carolina, Lalu, Manoj M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586991/ https://www.ncbi.nlm.nih.gov/pubmed/31276026 http://dx.doi.org/10.1016/j.omto.2019.05.004

Ejemplares similares

Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
por: Lalu, Manoj, et al.
Publicado: (2019)

Identifying barriers and enablers to rigorous conduct and reporting of preclinical laboratory studies
por: Lalu, Manoj M., et al.
Publicado: (2023)

Reporting preclinical anesthesia study (REPEAT): Evaluating the quality of reporting in the preclinical anesthesiology literature
por: Fergusson, Dean A., et al.
Publicado: (2019)

Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol
por: Lalu, Manoj M., et al.
Publicado: (2020)

Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews
por: Khan, Sarwat T, et al.
Publicado: (2020)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses
por: Forbes, Nicole E., et al.
Publicado: (2014)

Epidemiology and reporting characteristics of preclinical systematic reviews
por: Hunniford, Victoria T., et al.
Publicado: (2021)

Benefits and obstacles to cell therapy in neonates: The INCuBAToR (Innovative Neonatal Cellular Therapy for Bronchopulmonary Dysplasia: Accelerating Translation of Research)
por: Thébaud, Bernard, et al.
Publicado: (2021)

Definition and Characteristics of Mesenchymal Stromal Cells in Preclinical and Clinical Studies: A Scoping Review
por: Renesme, Laurent, et al.
Publicado: (2022)

Regenerative cell therapy for pulmonary arterial hypertension in animal models: a systematic review
por: Suen, Colin M., et al.
Publicado: (2019)

Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study
por: Castillo, Gisell, et al.
Publicado: (2021)

A systematic assessment of preclinical multilaboratory studies and a comparison to single laboratory studies
por: Hunniford, Victoria T, et al.
Publicado: (2023)

Patient engagement in preclinical laboratory research: A scoping review
por: Fox, Grace, et al.
Publicado: (2021)

Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy
por: Wilson, Mackenzie, et al.
Publicado: (2021)

A call to implement preclinical study registration in animal ethics review
por: Jeffers, Matthew S., et al.
Publicado: (2023)

Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial
por: Castillo, Gisell, et al.
Publicado: (2021)

Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials
por: Bastin, Donald J., et al.
Publicado: (2023)

Factors contributing to fidelity in a pilot trial of individualized resistant starches for pediatric inflammatory bowel disease: a fidelity study protocol
por: Castillo, Gisell, et al.
Publicado: (2021)

Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments
por: Henderson, Valerie C., et al.
Publicado: (2013)

Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials
por: Foster, Madison, et al.
Publicado: (2020)

The effects of resistant starches on inflammatory bowel disease in preclinical and clinical settings: a systematic review and meta-analysis
por: Montroy, Joshua, et al.
Publicado: (2020)

A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib
por: Henderson, Valerie C, et al.
Publicado: (2015)

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
por: Achard, Carole, et al.
Publicado: (2018)

On the same page? A qualitative study protocol on collaboration in a multi-laboratory preclinical study
por: Evans, Jenna M., et al.
Publicado: (2022)

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis
por: Grigor, Emma J M, et al.
Publicado: (2017)

Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol
por: Suen, Colin M., et al.
Publicado: (2016)

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner
por: El-Sayes, Nader, et al.
Publicado: (2022)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

Methods and efficacy of extracellular vesicles derived from mesenchymal stromal cells in animal models of disease: a preclinical systematic review protocol
por: Tieu, Alvin, et al.
Publicado: (2019)

Is preclinical research in cancer biology reproducible enough?
por: Kane, Patrick Bodilly, et al.
Publicado: (2021)

Establishment of a consensus definition for mesenchymal stromal cells (MSC) and reporting guidelines for clinical trials of MSC therapy: a modified Delphi study protocol
por: Renesme, Laurent, et al.
Publicado: (2021)

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV(POS) Cancers
por: Suksanpaisan, Lukkana, et al.
Publicado: (2018)

Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus
por: Cho, Euna, et al.
Publicado: (2018)

Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma
por: Kiyokawa, Juri, et al.
Publicado: (2019)

Assessment of safety and efficacy of mesenchymal stromal cell therapy in preclinical models of acute myocardial infarction: a systematic review protocol
por: Barron, Carly C., et al.
Publicado: (2017)

MSC-Derived Extracellular Vesicles to Heal Diabetic Wounds: a Systematic Review and Meta-Analysis of Preclinical Animal Studies
por: Bailey, Adrian J. M., et al.
Publicado: (2021)

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
por: Parato, Kelley A, et al.
Publicado: (2012)

The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research
por: Avey, Marc T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_434vbqch52t2jich0t3ot7f73o